Brazil's health regulator Anvisa seized one [1] falsified batch of the diabetes drug Mounjaro and ordered the recall of other medicines.
These actions are critical because counterfeit medications and mislabeled packaging can mislead patients and jeopardize public health. The regulator moved to ensure that patients do not administer incorrect or fraudulent dosages of critical medications.
Anvisa said the action occurred Wednesday, March 7, 2026 [1]. The agency identified a specific batch of Mounjaro that was falsified, leading to its immediate seizure [1]. Beyond the counterfeit drug, the regulator ordered a nationwide recall for other medications distributed by pharmaceutical companies. These additional recalls were triggered by packaging errors where labels had been mistakenly swapped [1].
The agency said that the packaging errors could lead to consumers taking the wrong medication. Because the error involved the physical containers of the drugs, Anvisa determined that a full recall was the only way to prevent potential patient harm [1].
Pharmaceutical companies distributing the affected medicines are working with the regulator to remove the products from the market. The agency has not specified the total number of patients affected by the swapped packaging, only that the risk to health prompted the safety precaution [1].
Patients who believe they have a product from the affected batches are advised to contact the distributor or the health regulator for guidance. Anvisa continues to monitor the supply chain for further instances of falsification in high-demand medications [1].
“Anvisa seized one falsified batch of the diabetes drug Mounjaro.”
The seizure of counterfeit Mounjaro reflects a growing global trend of falsified high-demand metabolic and diabetes medications. By targeting both counterfeits and pharmaceutical packaging errors, Anvisa is addressing two distinct failure points in the medical supply chain: criminal infiltration and industrial quality control. This suggests a heightened regulatory focus on the integrity of drug labeling to prevent accidental poisoning or treatment failure.
